SCD1 inhibitor-4 is primarily used in research and therapeutic applications targeting metabolic disorders and cancer. It works by inhibiting stearoyl-CoA desaturase-1 (SCD1), an enzyme involved in fatty acid metabolism. This inhibition can reduce the synthesis of monounsaturated fatty acids, which are implicated in insulin resistance, obesity, and tumor growth. In cancer studies, it has shown potential in suppressing tumor progression by disrupting lipid metabolism in cancer cells. Additionally, it is being explored for its role in managing metabolic syndromes, such as diabetes and non-alcoholic fatty liver disease, by improving insulin sensitivity and reducing lipid accumulation. Its application in preclinical models provides insights into its efficacy and safety for future therapeutic development.